PET imaging of translocator protein (18 kDa) in a mouse model of Alzheimer's disease using N-(2,5-dimethoxybenzyl)-2-18F-fluoro-N-(2-phenoxyphenyl)acetamide

Journal of Nuclear Medicine

Volumn 56, Issue 2, 2015, Pages 311-316

  James, Michelle L ^a,b   Belichenko, Nadia P ^b   Nguyen, Thuy Vi V ^b   Andrews, Lauren E ^a   Ding, Zhaoqing ^b,c   Liu, Hongguang ^a   Bodapati, Deepika ^a   Arksey, Natasha ^a   Shen, Bin ^a   Cheng, Zhen ^a   Wyss Coray, Tony ^b,c   Gambhir, Sanjiv S ^a   Longo, Frank M ^b   Chin, Frederick T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer's disease; Microglial activation; PET; Translocator protein 18 kDa

Indexed keywords

CD68 ANTIGEN; MITOCHONDRIAL PROTEIN; N (2,5 DIMETHOXYBENZYL) 2 FLUORO N (2 PHENOXYPHENYL)ACETAMIDE F 18; RADIOPHARMACEUTICAL AGENT; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; ACETANILIDE DERIVATIVE; BIOLOGICAL MARKER; BZRP PROTEIN, MOUSE; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; N-FLUOROACETYL-N-(2,5-DIMETHOXYBENZYL)-2-PHENOXYANILINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN REGION; CELL ACTIVATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DRUG ACCUMULATION; DRUG UPTAKE; EX VIVO STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; WILD TYPE; ANIMAL; DISEASE COURSE; DISEASE MODEL; METABOLISM; MUSCLE; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; TIME FACTOR;

ACETANILIDES; ALZHEIMER DISEASE; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AUTORADIOGRAPHY; BIOMARKERS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HIPPOCAMPUS; MAGNETIC RESONANCE IMAGING; MICE; MUSCLES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, GABA; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84922022681     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141648     Document Type: Article

References (30)

1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
2. Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis. 2010;37:503-509.
3. Weitz TM, Town T. Microglia in Alzheimer's disease: it's all about context. Int J Alzheimers Dis. 2012; 2012:314185.
4. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92:897-965.
5. Filippi M, Agosta F, Frisoni GB, et al. Magnetic resonance imaging in Alzheimer's disease: from diagnosis to monitoring treatment effect. Curr Alzheimer Res. 2012;9:1198-1209.
6. Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67-77.
7. Chen W, Song X, Beyea S, D'Arcy R, Zhang Y, Rockwood K. Advances in perfusion magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement. 2011;7:185-196.
8. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther. 2008;118:1-17.
9. Scarf AM, Kassiou M. The translocator protein. J Nucl Med. 2011;52:677-680.
10. Benavides J, Fage D, Carter C, Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 1987;421:167-172.
11. Wilms H, Claasen J, Röhl C, Sievers J, Deuschl G, Lucius R. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol Dis. 2003;14:417-424.
12. Owen DRJ, Matthews PM. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. Int Rev Neurobiol. 2011;101:19-39.
13. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461-467.
14. Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35:2304-2319.
15. Luus C, Hanani R, Reynolds A, Kassiou M. The development of PET radioligands for imaging the translocator protein (18 kDa): what have we learned? J Labelled Comp Radiopharm. 2010;53:501-510.
16. 18F-labeled ligand for PET imaging of brain peripheral benzodiazepine receptors [abstract]. J Labeled Compd Radiopharm. 2005;48.
17. 18F-PBR06, to image translocator protein (18 kDa). J Nucl Med. 2010;51:145-149.
18. Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of abeta(1-42). J Neurosci Res. 2001;66:573-582.
19. Nguyen T-VV, Shen L, Vander Griend L, et al. Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in ABPPL/S transgenic mice. J Alzheimers Dis. 2014;42:459-483.
20. 18F]PBR06. Mol Imaging Biol. 2014;16:109-117.
21. James ML, Shen B, Zavaleta CL, et al. New positron emission tomography (PET) radioligand for imaging s-1 receptors in living subjects. J Med Chem. 2012;55:8272-8282.
22. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci. 1994;83:1014-1019.
23. Waerzeggers Y, Monfared P, Viel T, Winkeler A, Jacobs AH. Mouse models in neurological disorders: applications of non-invasive imaging. Biochim Biophys Acta. 2010; 1802:819-839.
24. Cymerman U, Pazos A, Palacios JM. Evidence for species differences in "peripheral" benzodiazepine receptors: an autoradiographic study. Neurosci Lett. 1986;66: 153-158.
25. Krzyzanowska A, Carro E. Pathological alteration in the choroid plexus of Alzheimer's disease: implication for new therapy approaches. Front Pharmacol. 2012;3:75.
26. Serot JM, Béné MC, Foliguet B, Faure GC. Morphological alterations of the choroid plexus in late-onset Alzheimer's disease. Acta Neuropathol. 2000;99:105-108.
27. Hirvonen J, Kreisl WC, Fujita M, et al. Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. J Nucl Med. 2012;53:234-240.
28. Venneti S, Lopresti BJ, Wang G, et al. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging. 2009;30:1217-1226.
29. Maeda J, Zhang M-R, Okauchi T, et al. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci. 2011;31:4720-4730.
30. 18F]GE-180: a novel fluorine-18 labelled PET tracer for imaging translocator protein 18 kDa (TSPO). Bioorg Med Chem Lett. 2012;22:1308-1313.